DeutschNewstral
Article
Forbes on 2023-06-22 15:04
Eye-Catching Innovations: Gene Therapies For Retinal Disorders
Related news
Cancer Researchers Turn Focus to Gene TherapiesThe New York Times
FDA Issues Draft Guidance on Determining Sameness of Gene Therapiesjdsupra.com- FDA Announces New Policies to Advance Cell and Gene Therapiesjdsupra.com
- FDA Commissioner Plans to Create a Fast Track Approval Pathway for Certain Gene Therapiesjdsupra.com
- NFDA Approves Groundbreaking Cell-Based Gene Therapies for Sickle Cell Diseasennpa.org
- Stem Cell Therapies For Retinal Disorders Are A Sight For Sore EyesForbes
- Recent FDA Initiatives to Support Development of Individualized Cell and Gene Therapies and Rare Disease Therapiesjdsupra.com
Two gene therapies for sickle cell disease approved in USSeattle Times- FDA finalizes guidance on Orphan Drug “sameness” of gene therapiesjdsupra.com
Two gene therapies for sickle cell disease approved in U.S.staradvertiser.com
2 gene therapies for sickle cell disease approved in USAlaska Dispatch News- How Gene Editing Therapies Could Go Beyond Rare DiseasesForbes
- Gene Therapy Approvals Gain Steam in 2023: FDA Approves First Gene Therapies for Sickle Cell Diseasejdsupra.com
Sangamo and Novartis join forces to create gene therapies for autism and other brain disordersbizjournals.com- View from the Horizon: Digital Health and Cell, Tissue, and Gene Therapies in Bostonjdsupra.com
- Regulatory Insights for Life Sciences and Health Care Investments: Cell and gene therapiesjdsupra.com
- FDA Clarifies and Expands Eligibility for RMAT Designation for Gene Therapiesjdsupra.com
- Passage Bio secures FDA fast track status for three 'potentially transformative' gene therapiesbizjournals.com
- Capsida Biotherapeutics Debuts with $140 Million of Capital for its AAV Gene Therapiesjdsupra.com